HMGCR and Hutchinson-Gilford progeria syndrome: Contrary to this hypothesis, in a mouse model of premature aging Hutchinson–Gilford progeria syndrome (HGPS), a treatment combination of the bisphosphonate zoledronic acid together with pravastatin (which also acts in the HMG-CoA-reductase pathway in liver) significantly reduced accumulation of AGEs and improved HGPS-induced bone defects (Cubria et al., 2020).